Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) Accumulated Depreciation & Amortization (2016 - 2025)

Neurocrine Biosciences' Accumulated Depreciation & Amortization history spans 15 years, with the latest figure at $118.3 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 11.08% year-over-year to $118.3 million; the TTM value through Dec 2025 reached $118.3 million, up 11.08%, while the annual FY2025 figure was $118.3 million, 11.08% up from the prior year.
  • Accumulated Depreciation & Amortization reached $118.3 million in Q4 2025 per NBIX's latest filing, up from $106.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $118.3 million in Q4 2025 to a low of $51.9 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $85.2 million, with a median of $83.0 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: increased 28.31% in 2024, then increased 11.08% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $51.9 million in 2021, then rose by 27.75% to $66.3 million in 2022, then rose by 25.19% to $83.0 million in 2023, then grew by 28.31% to $106.5 million in 2024, then rose by 11.08% to $118.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Accumulated Depreciation & Amortization are $118.3 million (Q4 2025), $106.5 million (Q4 2024), and $83.0 million (Q4 2023).